Survivin Splice Variants in Arsenic Trioxide (As₂O₃)-Induced Deactivation of PI3K and MAPK Cell Signalling Pathways in MCF-7 Cells.
apoptosis
arsenic trioxide
breast cancer
cell cycle
survivin splice variants
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
14 01 2019
14 01 2019
Historique:
received:
19
11
2018
revised:
30
12
2018
accepted:
08
01
2019
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
17
1
2019
Statut:
epublish
Résumé
Several pathways are deregulated during carcinogenesis but most notably, tumour cells can lose cell cycle control and acquire resistance to apoptosis by expressing a number of anti-apoptotic proteins such as the Inhibitors of Apoptosis Protein (IAP) family of proteins that include survivin, which is implicated in cancer development. There is no study which had proven that arsenic trioxide (As₂O₃) has any effect on the splicing machinery of survivin and its splice variants, hence this study was aimed at determining the cytotoxic effect of As₂O₃ and its effect on the expression pattern of survivin splice variants in MCF-7 cells. As₂O₃ inhibited the growth of the MCF-7 cells in a concentration-dependent manner. The Muse
Identifiants
pubmed: 30646589
pii: genes10010041
doi: 10.3390/genes10010041
pmc: PMC6356383
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Survivin
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Arsenic Trioxide
S7V92P67HO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Toxicol Appl Pharmacol. 2015 May 15;285(1):41-50
pubmed: 25791921
Nature. 1998 Dec 10;396(6711):580-4
pubmed: 9859993
Toxicol Lett. 2015 Jan 22;232(2):481-9
pubmed: 25436934
Cancer Treat Rev. 2013 Nov;39(7):802-11
pubmed: 23453862
Nat Cell Biol. 1999 Dec;1(8):461-6
pubmed: 10587640
Cancer Cell Int. 2016 Jun 23;16:49
pubmed: 27340370
Endocr Relat Cancer. 2011 Dec 01;18(6):783-92
pubmed: 21878572
Life Sci. 2002 Jun 7;71(3):275-85
pubmed: 12034346
Cancer Lett. 2009 Nov 1;284(2):208-15
pubmed: 19457607
Exp Ther Med. 2011 May;2(3):481-486
pubmed: 22977528
Int J Oncol. 2005 Oct;27(4):1151-7
pubmed: 16142334
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104
pubmed: 26931810
Int J Mol Sci. 2012;13(8):9627-41
pubmed: 22949821
Oncotarget. 2014 May 30;5(10):3333-49
pubmed: 24830600
BMC Cancer. 2014 Mar 12;14:176
pubmed: 24620748
Cell Death Differ. 2010 Dec;17(12):1867-81
pubmed: 20508647
Stem Cell Res. 2014 Mar;12(2):539-49
pubmed: 24487129
Cancer Chemother Pharmacol. 2015 Dec;76(6):1101-12
pubmed: 26563258
Basic Res Cardiol. 2011 Nov;106(6):1207-20
pubmed: 21706383
Br J Cancer. 2016 Feb 16;114(4):427-34
pubmed: 26882066
Front Pharmacol. 2016 Mar 31;7:81
pubmed: 27065869
Cell Death Dis. 2018 Oct 15;9(11):1050
pubmed: 30323195
J Cancer. 2015 Feb 06;6(4):319-26
pubmed: 25767601
Clin Breast Cancer. 2014 Apr;14(2):122-31
pubmed: 24325949
Cell Death Differ. 2017 Aug;24(8):1390-1400
pubmed: 28362431
Arch Toxicol. 2006 Jun;80(6):310-8
pubmed: 16328441
Int J Mol Sci. 2018 Mar 24;19(4):
pubmed: 29587347
Biochem Biophys Res Commun. 2003 Jan 3;300(1):230-5
pubmed: 12480548
Molecules. 2017 Mar 14;22(3):
pubmed: 28335434
Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103
pubmed: 25936818
Int J Oncol. 2015 Feb;46(2):841-8
pubmed: 25405645
Cancer Biother Radiopharm. 2012 Oct;27(8):504-12
pubmed: 22988968
Surg Oncol. 2012 Jun;21(2):125-31
pubmed: 21334875
Biochem Pharmacol. 2014 May 1;89(1):31-42
pubmed: 24560876
Arch Drug Inf. 2009 Dec;2(4):59-65
pubmed: 20098508
Contemp Oncol (Pozn). 2015;19(2):108-12
pubmed: 26034387
Autophagy. 2009 May;5(4):472-83
pubmed: 19242099
Biochim Biophys Acta. 2010 Apr;1802(4):396-405
pubmed: 20079433
J Cancer. 2015 Sep 15;6(11):1187-94
pubmed: 26516368